CA Patent

CA3235132A1 — Antibody drug conjugates and methods for making thereof

Assigned to Novartis AG · Expires 2022-10-20 · 4y expired

What this patent protects

This application discloses microorganisms and methods of producing GNAQ/GNAll inhibitors and methods of making antibody drug conjugates of anti-PMEL17 antibodies or antigen binding fragments conjugated to a GNAQ/GNAll inhibitor. The disclosure also relates to formulations compris…

USPTO Abstract

This application discloses microorganisms and methods of producing GNAQ/GNAll inhibitors and methods of making antibody drug conjugates of anti-PMEL17 antibodies or antigen binding fragments conjugated to a GNAQ/GNAll inhibitor. The disclosure also relates to formulations comprising antibody drug conjugates of anti-PMEL17 antibodies or antigen binding fragments conjugated to a GNAQ/GNAll inhibitor and methods of treating or preventing cancer using the fommlations.

Drugs covered by this patent

Patent Metadata

Patent number
CA3235132A1
Jurisdiction
CA
Classification
—
Expires
2022-10-20
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.